BTK and diffuse large B-cell lymphoma: In a phase 1/2 clinical trial involving 80 subjects with RR DLBCL, use of the BTK inhibitor ibrutinib led to complete or partial responses in 37% (n=14/38) of subjects with ABC DLBCL suggesting that BTK inhibition is insufficient therapy for ABC-DLBCL (41).